InflaRx N.V. IFRX
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- +7.92%
- 1 year
- -13.49%
- Market cap
- 160.63M
- Revenue (ttm)
- 105.48K
- EPS (ttm)
- -0.37
- Shares out
- 58.88M
- Forward P/E
- -2.36
- YTD return
- +7.92%
- 1-year return
- -13.49%
- 50-day average
- 1.91
- 200-day average
- 1.61
- Volume
- 664.90K
- Avg volume
- 866.64K
- Open
- 1.11
- Previous close
- 1.11
- Day's range
- 1.09 – 1.13
- 52-week range
- 0.798 – 2.95
- Beta
- 1.58
- Analysts
- Buy
- Price target
- 8.09 (+642.2%)
Key statistics
- Enterprise value
- 70.76M
- Price / sales
- 1395.56
- Price / book
- 1.44
- Free cash flow
- -2.12M
- Total cash
- 19.15M
- Total debt
- 998.67K
- Return on equity
- -45.34%
- Short % of float
- 0.44%
Fundamental scorecard
5 of 25 checks passed on IFRX’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.27 | -0.33 | -0.06 | -22.22% |
| Aug 8, 2024 | Jun 1, 2024 | -0.21 | -0.26 | -0.05 | -23.81% |
| Aug 8, 2024 | Jun 1, 2024 | -0.21 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.24 | -0.19 | +0.05 | +20.83% |
| May 8, 2024 | Mar 1, 2024 | -0.24 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.20 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- Website
- inflarx.de
News
12 Health Care Stocks Moving In Friday's After-Market Session
Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now
Down 20.3% in 4 Weeks, Here's Why You Should You Buy the Dip in InflaRx (IFRX)
Head-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX) InflaRx Announces Peer-Reviewed Publication Of First-In-Human Phase 1 Clinical Data For Izicopan, Orally Administered, Next-Gen Small Molecule Inhibitor Of C5a Receptor
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
InflaRx N.V. (IFRX) Analyst/Investor Day Transcript
InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials InflaRx Q3 EPS $(0.02) Beats $(0.07) Estimate
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
Your note
Sign in to keep a note on IFRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.74% | 5,733,910 | 14.33M | Sep 29, 2024 |
| 683 Capital Management LLC | 3.52% | 2,070,000 | 5.17M | Sep 29, 2024 |
| Eversept Partners, LP | 2.75% | 1,621,787 | 4.05M | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 1.36% | 797,876 | 1.99M | Sep 29, 2024 |
| Ikarian Capital, LLC | 1.20% | 704,987 | 1.76M | Sep 29, 2024 |
| Morgan Stanley | 1.13% | 668,131 | 1.67M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 36,236 | 90.59K | Oct 30, 2024 |
